American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting

The Effect of Benralizumab On Allergen-Induced Responses In Subjects With Mild Allergic Asthma [Abstract 500]

Elimination of Oral Corticosteroids (OCS) with Benralizumab Treatment in OCS-Dependent Asthmatics Using a Rapid, Personalized Algorithm:The PONENTE Trial

Biologic Pathways Involved in Chronic Spontaneous Urticaria and Response to Benralizumab Treatment [Abstract 501]

Clinical and Economic Burden of Patients with Uncontrolled Severe Asthma with Low Blood Eosinophil Levels in the United States

Efficacy And Safety Of Tezepelumab In Adults And Adolescents With Severe, Uncontrolled Asthma:Results From The Phase 3 NAVIGATOR Study

Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY phase 2b study

Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals

Baseline Asthma Impairment and Risk Questionnaire (AIRQ™) Control Level is Associated with Future Risk of Exacerbations [Abstract 148]

Which Severe Asthma Patients Are Switching, Stopping, or Continuing Biologic Treatments? [Abstract 178]

Effects of Sex and Age on Characteristics of US Patients with Severe Asthma [Abstract 147]